Second pass at: Cagrilintide molecular characteristics and analytical considerations

On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion.

Something about Cagrilintide molecular characteristics and analytical does not reconcile and I would like a second pair of eyes before I decide which half is wrong.

Two sources, both reputable, giving figures that cannot both be right unless they are measuring different quantities. My suspicion is that they are, and I cannot see how.

The opening post and I disagree about the size of the effect, not about the direction.

Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.

Anyone reading a purity result for cagrilintide should know that its aggregation behaviour makes sample handling matter more than usual. A result on a sample that was warmed and cooled several times in transit is measuring the transit as much as the material.

If the premise is wrong, everything after it is decoration.

Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.

The claim is narrower than it sounds, and deliberately so.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

The general case is well covered; this is the awkward specific one.